Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Frankel

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Medical Economics|March 14, 2007
The ABCs of IMEs. An experienced hand reveals how to conduct independent medical examsJeffrey Frankel
Urology Practice|February 2, 2024
Stepping Away From Step Therapy for Overactive Bladder: The Role of Urologists in Advocating for Step Therapy ReformsJeffrey Frankel
Therapeutic Advances in Urology|January 21, 2025
Plain Language Summary of Publication: What is the effect of the medicine vibegron in the treatment of overactive bladder in patients with and without bladder leakage?David Staskin, Jeffrey Frankel, Steven G Gregg, et al.
Journal of Comparative Effectiveness Research|August 16, 2023
Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR studyDavid Staskin, Jeffrey Frankel, Steven G Gregg, et al.
The Journal of Urology|February 19, 2020
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWURDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
The Journal of Urology|March 9, 2021
Reply by AuthorsDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
International Journal of Clinical Practice|December 17, 2020
Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR studyJeffrey Frankel, Susann Varano, David Staskin, et al.
The Journal of Urology|December 28, 2020
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)David Staskin, Jeffrey Frankel, Susann Varano, et al.
Drugs & Aging|January 20, 2021
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III StudySusann Varano, David Staskin, Jeffrey Frankel, et al.
The Journal of Urology|May 22, 2020
Reply by AuthorsDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Medical Economics|March 14, 2007
The ABCs of IMEs. An experienced hand reveals how to conduct independent medical examsJeffrey Frankel
Urology Practice|February 2, 2024
Stepping Away From Step Therapy for Overactive Bladder: The Role of Urologists in Advocating for Step Therapy ReformsJeffrey Frankel
Therapeutic Advances in Urology|January 21, 2025
Plain Language Summary of Publication: What is the effect of the medicine vibegron in the treatment of overactive bladder in patients with and without bladder leakage?David Staskin, Jeffrey Frankel, Steven G Gregg, et al.
Journal of Comparative Effectiveness Research|August 16, 2023
Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR studyDavid Staskin, Jeffrey Frankel, Steven G Gregg, et al.
The Journal of Urology|February 19, 2020
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWURDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
The Journal of Urology|March 9, 2021
Reply by AuthorsDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
International Journal of Clinical Practice|December 17, 2020
Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR studyJeffrey Frankel, Susann Varano, David Staskin, et al.
The Journal of Urology|December 28, 2020
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)David Staskin, Jeffrey Frankel, Susann Varano, et al.
Drugs & Aging|January 20, 2021
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III StudySusann Varano, David Staskin, Jeffrey Frankel, et al.
The Journal of Urology|May 22, 2020
Reply by AuthorsDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
Pageof 2